ASCO GU Conference Coverage
Filter News By:
Featured Articles
(Medscape Medical News) Feb 17, 2020 - For the first time, a clear cell renal cell carcinoma therapy targets a molecular driver of the cancer that was previously believed to be "undruggable," said investigator Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, here at the Genitourinary Cancers Symposium (GUCS)...
Read Article
(MedPage Today) Feb 15, 2020 - Patients with cisplatin-ineligible advanced bladder cancer achieved durable objective responses with the combination of pembrolizumab (Keytruda) and a newly approved antibody-drug conjugate (ADC), new data from a phase I trial showed. Overall, 33 of 45 patients responded to pembrolizumab and enfortumab...
Read Article
Latest Articles
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
View More
News Commentary
There is no ASCO GU Conference Coverage commentary.

OBR Green
There are no ASCO GU Conference Coverage OBR Green articles.
OBR Blog
There are no ASCO GU Conference Coverage blog entries.

OBR Tweets

Feb 20
H. Jack West, MD: The results with atezolizumab in this highly enriched subset echo the findings with pembrolizumab… https://t.co/KbOYjNqeHc

Feb 19
Howard S. Hochster, MD: Another "swing and a miss" in pancreatic cancer. Despite numerous trial of chemotherapy pl… https://t.co/mAuyJZE4fa

Feb 18
William McGivney, PhD: Every once in a while, in my columns, I mention that Rick Pazdur, MD of the FDA NEEDS to be… https://t.co/SgpegJSMWB

Feb 17
Nizar Tannir, MD, of @MDAndersonNews describes the 4 year follow up study of nivolumab + ipilimumab in RCC patients… https://t.co/RY6WXLDL1N

Feb 17
Bradley McGregor, MD @BradMcG04, of @DanaFarber on impressions of phase I/II study of oral HIF-2 α inhibitor MK-648… https://t.co/EPvkjmtsb4

Feb 17
David Quinn, MD, of @KeckMedUSC on impressions of phase I/II study of oral HIF-2 α inhibitor MK-6482 in patients wi… https://t.co/rBvAje1it1

Feb 17
Scott Tawaga, MD, of @WeillCornell on promising PSMA products in development for prostate cancer treatment #GU20 https://t.co/BLfI32lWzS

Feb 17
Tian Zhang, MD, MHS @TiansterZhang, of @DukeCancer elaborates on the PEDIGREE clinical study in advanced renal cell… https://t.co/kgdQPTsquK

Feb 17
Bradley McGregor, MD @BradMcG04, of @DanaFarber describes whether biomarkers will help guide treatment in advanced… https://t.co/2uejg888Ui

Feb 17
Michael Atkins, MD, of @LombardiCancer on follow up investigation of Checkmate 025 in renal cell carcinoma patients… https://t.co/2dyPZwc8dF